Manno-oligosaccharides as a promising antimicrobial strategy: pathogen inhibition and synergistic effects with antibiotics.

IF 4 2区 生物学 Q2 MICROBIOLOGY
Frontiers in Microbiology Pub Date : 2025-03-24 eCollection Date: 2025-01-01 DOI:10.3389/fmicb.2025.1529081
Rachel E Asbury, Bradley A Saville
{"title":"Manno-oligosaccharides as a promising antimicrobial strategy: pathogen inhibition and synergistic effects with antibiotics.","authors":"Rachel E Asbury, Bradley A Saville","doi":"10.3389/fmicb.2025.1529081","DOIUrl":null,"url":null,"abstract":"<p><p>Infections caused by pathogenic bacteria pose a significant health challenge to humans and animals, especially given the rising incidence of antimicrobial resistance. Addressing this challenge has resulted in initiatives seeking alternatives to traditional antibiotics. Manno-oligosaccharides (MOS) exhibit pathogen-binding properties, due to their ability to prevent bacterial adhesion to epithelial cells, such as those within the urinary tract and intestinal epithelium. This suggests that MOS could offer a promising alternative to antibiotics. In this study, we explore the ability of various <i>β</i>-MOS products to inhibit the growth of <i>Escherichia coli, Klebsiella pneumoniae, Listeria monocytogenes,</i> and <i>Streptococcus mutans</i>, in addition to their ability to render antibiotics more effective. Inhibition profiles were distinct for each bacterial strain and differed according to <i>β</i>-MOS structure. Antibiotics were significantly potentiated by MOS in some cases, such as ceftazidime against <i>K. pneumoniae</i>. This research shows the role of carbohydrate structure in the anti-bacterial properties of non-digestible oligosaccharides such as MOS and positions MOS as a promising strategy in the treatment of bacterial infections.</p>","PeriodicalId":12466,"journal":{"name":"Frontiers in Microbiology","volume":"16 ","pages":"1529081"},"PeriodicalIF":4.0000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973258/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Microbiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.3389/fmicb.2025.1529081","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Infections caused by pathogenic bacteria pose a significant health challenge to humans and animals, especially given the rising incidence of antimicrobial resistance. Addressing this challenge has resulted in initiatives seeking alternatives to traditional antibiotics. Manno-oligosaccharides (MOS) exhibit pathogen-binding properties, due to their ability to prevent bacterial adhesion to epithelial cells, such as those within the urinary tract and intestinal epithelium. This suggests that MOS could offer a promising alternative to antibiotics. In this study, we explore the ability of various β-MOS products to inhibit the growth of Escherichia coli, Klebsiella pneumoniae, Listeria monocytogenes, and Streptococcus mutans, in addition to their ability to render antibiotics more effective. Inhibition profiles were distinct for each bacterial strain and differed according to β-MOS structure. Antibiotics were significantly potentiated by MOS in some cases, such as ceftazidime against K. pneumoniae. This research shows the role of carbohydrate structure in the anti-bacterial properties of non-digestible oligosaccharides such as MOS and positions MOS as a promising strategy in the treatment of bacterial infections.

甘露寡糖作为一种有前途的抗菌策略:病原体抑制及其与抗生素的协同作用。
致病菌引起的感染对人类和动物的健康构成重大挑战,特别是考虑到抗菌素耐药性的发病率不断上升。为应对这一挑战,已采取行动寻求传统抗生素的替代品。甘露寡糖(MOS)表现出病原体结合特性,因为它们能够防止细菌粘附在上皮细胞上,如尿路和肠上皮内的细胞。这表明MOS可能是抗生素的一个有希望的替代品。在这项研究中,我们探索了各种β-MOS产物抑制大肠杆菌、肺炎克雷伯菌、单核细胞增生李斯特菌和变形链球菌生长的能力,以及它们使抗生素更有效的能力。不同菌株的抑制效果不同,β-MOS结构也不同。在某些情况下,抗生素被MOS显著增强,如头孢他啶对肺炎克雷伯菌的作用。这项研究显示了碳水化合物结构在不可消化低聚糖(如MOS)的抗菌特性中的作用,并将MOS作为治疗细菌感染的有前途的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.70
自引率
9.60%
发文量
4837
审稿时长
14 weeks
期刊介绍: Frontiers in Microbiology is a leading journal in its field, publishing rigorously peer-reviewed research across the entire spectrum of microbiology. Field Chief Editor Martin G. Klotz at Washington State University is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信